Drug Database
CT

CTC-111 (Anact C)

✓ Approved

Meiji Holdings · PROC

What is CTC-111?

CTC-111 is a therapeutic agent developed by Meiji Holdings. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAnact C
CompanyMeiji Holdings
Molecular TargetPROC
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Mechanism of Action

Molecular Targets

CTC-111 acts on 1 molecular target:

PROCprotein C, inactivator of coagulation factors Va and VIIIa (APC, PROC1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

CTC-111 is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved
Skin and subcutaneous tissue disordersPurpura fulminans✓ Approved

Related Research Articles

PubMedChemical communications (Cambridge, England)2026-07-25

Toluene formation via acetylene-propyne cyclotrimerization on Ag(111).

Dewage Nipun T S K NTSK, Biswas Santu S, Sykes E Charles H ECH, Montemore Matthew M MM et al.

Selective C-C coupling between different alkynes on metal surfaces remains largely unexplored. Here, we show that coadsorbed acetylene and propyne on Ag(111) form toluene through a C2-C3 cross-cyclotrimerization pathway that competes with acetylene homotrimerization to benzene. Our study reveals how molecular-scale co-assemblies affect competing energy barriers which in turn govern reaction selectivity to benzene and toluene. These results extend efficient acetylene trimerization chemistry to hetero-alkyne coupling on metal surfaces. This work establishes a molecular-level framework for controlling hetero-alkyne cyclotrimerization and opens new opportunities for C2/C3 upgrading to substituted aromatics.

PMID 42498267
Read full article →
PubMedOncology research2026-07-25

Breast Cancer Cell-Derived Exosomal miR-92b-3p Promotes Tumor Angiogenesis and Metastasis by Suppressing PTEN in Vascular Endothelial Cells.

Yang Tingting T, Guan Meng M, Guan Xin X, Kang Lihua L et al.

Background: Tumor-driven vascular remodeling is crucial for breast cancer metastasis; yet, the role of tumor-derived exosomal miRNAs in this process remains underexplored. This study aimed to investigate the clinical relevance and the underlying mechanism of breast cancer-derived exosomal miR-92b-3p in endothelial reprogramming. Methods: miR-92b-3p expression was evaluated in the TCGA cohort and clinical patient samples. The effects of exosomal miR-92b-3p from breast cancer cells on recipient human microvascular endothelial cells (HMVECs) were assessed using in vitro angiogenesis, migration, and permeability assays, alongside in vivo murine xenograft models. Mechanistic targets were validated via dual-luciferase and rescue experiments. Results: miR-92b-3p was significantly upregulated in breast cancer tissues and plasma exosomes, correlating with advanced stages, poor survival, and exhibiting high diagnostic accuracy. Breast cancer-derived exosomes effectively transferred miR-92b-3p into HMVECs, significantly promoting angiogenesis, endothelial migration, and transendothelial permeability. In vivo, overexpression of miR-92b-3p accelerated tumor growth, vascularization, and circulating tumor cell (CTC) dissemination. Mechanistically, exosomal miR-92b-3p directly targeted and suppressed PTEN in endothelial cells; moreover, restoring PTEN expression fully abrogated the exosome-induced pro-angiogenic and hyperpermeable phenotypes. Conclusions: Breast cancer-derived exosomal miR-92b-3p disrupts the vascular barrier and promotes tumor angiogenesis by targeting endothelial PTEN, thereby facilitating metastasis. Circulating exosomal miR-92b-3p represents a promising candidate liquid-biopsy biomarker for breast cancer progression.

PMID 42500570
Read full article →
PubMedRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026-07-25

Metformin + Insulin vs. Insulin for GDM and T2DM during pregnancy: systematic review and meta-analysis.

Hallack Christiano C, Nogueira Bernardo Vieira BV, Bomfim Maressa M, Meireles Nathália N et al.

Evaluate the effectiveness and safety of adding metformin to insulin (M+I) versus insulin alone for pregnant women with type 2 diabetes mellitus (T2DM) or gestational diabetes mellitus (GDM), focusing on stillbirth as the primary outcome. PubMed, Embase, and Cochrane Central were searched. No date limits. Last search: January 2025. Randomized clinical trials including women with T2DM or GDM were eligible. Trials restricted to type 1 diabetes were excluded. Two reviewers extracted maternal and neonatal outcomes and assessed risk of bias with the Cochrane RoB 2 tool. Evidence certainty was graded using GRADE. Data were pooled with random-effects models and reported as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals. Nine RCTs (2,420 women) were included, most with GDM and some with T2DM. Moderate-quality evidence indicated reduced stillbirth risk with M+I (6 RCTs, 2,196 participants; RR 0.36, 95% CI 0.14-0.90; NNT 111). Low-quality evidence suggested lower risks of gestational hypertension (4 RCTs; RR 0.68, 95% CI 0.48-0.97) and neonatal hypoglycemia (7 RCTs; RR 0.49, 95% CI 0.30-0.80). No significant differences were found for cesarean section, preterm delivery, or other neonatal outcomes. Heterogeneity, baseline imbalances, and small samples limited certainty. M+I may reduce stillbirth and some adverse outcomes compared with insulin alone, but most evidence remains low certainty. Further high-quality RCTs are needed.Registered in PROSPERO: CRD42024617330.

PMID 42500179
Read full article →
PubMedJournal of acquired immune deficiency syndromes (1999)2026-07-25

Associations between pain, mobility, quality of life and mental health in people of Black ethnicities with HIV in London.

Hull Tamzin T, Dominguez-Dominguez Lourdes L, Campbell Lucy L, Fox Julie J et al.

Chronic pain, and its relationship with physical function and mental health, remains under-explored in people of Black ethnicities with HIV who experience intersecting inequities which may affect the experience and impact of pain. We investigated associations between severity of pain, physical function and mental health in these populations. Three HIV clinics in South London, UK. We conducted a cross-sectional study in adults of Black ethnicities with HIV. Multivariable logistic regression analysis was used to examine associations between mild and moderate-severe pain, physical function and mental health. We enrolled 398 participants (median age 52 years, 55% female); 16% reported mild pain and 25% moderate-severe pain. In multivariable analysis, moderate-severe pain (vs. no pain) was associated with moderate-severely impaired mobility (adjusted odds ratio [aOR] 72.6 [25.7, 250]), moderate-severely impaired ability to self-care (aOR 16.4 [4.1, 111]), moderate-severely impaired ability to perform usual activities (aOR 14.9 [6.3, 37.4]), and poor mental health (aOR 9.2 [5.1, 17.1]), and mild pain with mild and moderate-severe impairment of mobility (aOR 6.5 [2.5, 17.8] and 5.2 [1.5, 18.8] respectively), mild impairment in the ability to perform usual activities (aOR 4.8 [1.9, 11.9), and poor mental health (aOR 2.4 [1.2, 4.8]). In this sample of people of Black ethnicities with HIV, two-fifths reported pain. Pain, regardless of severity, was associated with mobility impairment, difficulties performing activities of daily living, and poor mental health. We recommend evaluation of pain in HIV clinical services and establishing robust pain management pathways to maximise quality of life.

PMID 42498454
Read full article →
PubMedACS physical chemistry Au2026-07-25

Emergent Rate Laws for Collective Lying-Standing Transitions.

Werkovits Anna A, Hollweger Simon B SB, Hofmann Oliver T OT

Lying-standing transitions in the first molecular monolayer at organic-inorganic interfaces strongly influence interface dipoles, energy-level alignment, and growth modes, yet their collective kinetics remain difficult to predict. Here, we establish a quantitative adsorbate-to-kinetics relationship for such transitions using first-principles-based kinetic Monte Carlo simulations combined with a mean-field-type coarse-graining strategy. Focusing on the prototypical system tetracyanoethylene on Cu(111), we show that the collective transition rate cannot be inferred from any single elementary step but instead emerges from a small set of coupled microscopic processes, including reorientation, adsorption, and diffusion. A local two-step reorientation mechanism captures the diffusion-limited regime, while diffusion of lying molecules accelerates the transition in diffusion-enhanced regimes by sterically suppressing back-reorientation via vacancy-molecule decoupling. This effect is captured by a regime-dependent geometric factor that quantitatively accounts for deviations between single-molecule and collective rate constants. By systematically varying molecular size and footprint ratio, we demonstrate that geometry provides a powerful intrinsic control parameter. While the collective rate scales approximately proportionally with molecular area, increasing the footprint ratio between lying and standing configurations leads to order-of-magnitude accelerations due to enhanced vacancy creation and diffusion-assisted stabilization. Based on these results, we derive an explicit analytical expression for the collective reorientation rate constant that links temperature- and pressure-dependent microscopic rate constants to geometric parameters. The resulting formulation quantitatively reproduces the simulation results across kinetic regimes and provides transferable design principles for engineering lying-standing transition time scales at organic-inorganic interfaces.

PMID 42500221
Read full article →
PubMedAmerican journal of hematology2026-07-25

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

Alsugair Ali A, Fathima Saubia S, Alhousani Mohammad M MM, Mariotti Estefania Gauto EG et al.

The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST-Mol) differentiate low, intermediate, and high-risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients (n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST-Mol risk categories. At a median follow-up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non-ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non-ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high-risk (median 50 vs. 14 months; p < 0.01), intermediate-risk (81 vs. 28 months; p < 0.01), and low-risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST-Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time-dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST-Mol high- and intermediate-risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST-Mol high- and intermediate-risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.

PMID 42499183
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about CTC-111